Clinical study of gene therapy for AADC deficiency - Clinical study of gene therapy for AADC deficiency

Kojima Karin0 sites8 target enrollmentMarch 15, 2019

Overview

No summary available.

Registry

who.int

Start Date

March 15, 2019

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Kojima Karin

•1\)Patients who have AADC deficiency with symptoms such as motor dysfunction and dystonia, and whose diagnosis has been confirmed by cerebrospinal fluid inspection findings, by enzyme activity measurement, or by genetic diagnosis.
•2\)Patients aged 2 years or older at the time of treatment.
•3\)Patients who do not show findings suggesting any other neurodegenerative disease.
•4\)Patients who are able to abide by the conditions essential for the research, including frequent medical examinations after the treatment.
•5\)Patients who have not changed any medications for at least 1 month prior to participation in this research.
•6\)Patients whose families have had a full explanation, have given their consent, and have signed the consent form.

•1\) Patients with cerebrovascular disease or other clear cardiovascular disease.
•2\) Patients who also have an intracerebral malignant neoplasm or other clinically evident neurological disorder.
•3\) Patients who have completed treatment for any malignant tumor other than skin cancer within the last 5 years.
•4\) Patients with high blood pressure (systolic blood pressure 160 mmHg or more).
•5\) Patients with blood coagulation disorder, or patients that require anticoagulant therapy.
•6\) Patients with a clinically evident immune disorder, or who require immunosuppressive agents.
•7\) Patients who cannot have MRI scans.
•8\) Patients in whom the generally recognized abnormal findings of AADC deficiency are not present on FMT\-PET prior to the treatment.
•9\) Patients with a severe allergy to medication.
•10\)Patients who have taken part in a different clinical trial within the past 6 months.